• Virtual Site Brings Speed, Diversity, And Engagement To Digital Therapeutic Trial

    Clinical Research News | Digital therapeutics are a natural fit with the decentralized clinical trial model and the COVID-19 pandemic has been a major driver of demand for both. The hybrid-designed PROSPER-FM trial is a good case in point. The devices being studied are a digital Acceptance and Commitment Therapy program and digital symptom tracker for adults with fibromyalgia and the single virtual site, run by Curavit, has been enrolling 10 times more patients than all other bricks-and-mortar sites starting at the same time.

    Jan 11, 2023

  • SCOPE Preview: Patient-Centricity, Real-World Evidence, and the Evolution of Clinical Trial Design

    Clinical Research News | Clinical Research News will be attending the Summit for Clinical Ops Executives—SCOPE—in Orlando, Fla. from February 6-9, 2023. Here are just a few of the items from the agenda we’ve flagged so far.

    Jan 10, 2023

  • Trendspotting: Hybrid and Decentralized Clinical Trials, Patient-Centricity, and Increased Remote Patient Monitoring in 2023

    Clinical Research News | We spoke with clinical research leaders about their expectations for the coming year. They predicted that hybrid and decentralized trials (DCTs) would eventually become the industry standard, brick-and-mortar sites will employ flexibility to increase patient retention, and companies will rely heavily on remote patient monitoring and wearable devices to stretch their budgets and combat the looming economic downturn.

    Jan 5, 2023

  • AbbVie’s Christopher Boone on Disrupting the Clinical Research Enterprise With Real-World Data and Evidence

    Clinical Research News | In recent years, pharmaceutical and life science companies have leveraged real-world evidence (RWE) to maximize patient recruitment and formulate clinical trial criteria. In the latest episode of the Scope of Things podcast, Christopher Boone, Ph.D., vice president and global head of health economics and outcomes research at AbbVie, talks about the disruptive nature of RWE and its impact on clinical trial design.

    Jan 3, 2023